How India Is Speeding Up Drug Approvals — And What It Means for Patients

When a new medicine is developed anywhere in the world, it cannot simply be sold in India. It must first go through India's drug approval process — a regulatory journey overseen by the Central Drugs Standard Control Organisation (CDSCO) and its head, the Drug Controller General of India (DCGI). Until recently, this journey was often described as slow, unpredictable, and burdensome.

That is changing rapidly. A series of reforms under CDSCO are shortening approval timelines, bringing greater transparency, and aligning India more closely with global regulatory standards. For patients, this could mean faster access to newer, more effective medicines.

Why Drug Approval Reform Matters

Every day a new medicine sits in regulatory review is a day it is not available to patients who might benefit from it. For diseases with few existing treatment options — certain cancers, rare genetic conditions, drug-resistant infections — delays in drug approvals are not just an administrative inconvenience. They are a matter of life and death.

At the same time, rushed approvals without adequate safety review can cause harm at scale. The history of medicine includes cases where insufficiently evaluated drugs caused serious adverse effects — some of which were only discovered after widespread use. India's reform agenda has to balance both these realities: faster access and uncompromised safety.

The Old System: What Was Wrong?

Under the previous framework governed by Schedule Y of the Drugs and Cosmetics Rules, 1945 and subsequently the New Drugs and Clinical Trials Rules, 2019, India required local clinical trials for most new drugs — even if the drug had already completed extensive global trials and been approved by the US FDA, EU's EMA, or other major regulators.

This meant:

• Duplicate trials — Indian patients had to re-participate in trials for drugs already proven safe globally
• Delays of several years — by the time a new drug was approved in India, it had often been available in other countries for 3–5 years
• Lack of process clarity — expert committee decisions were inconsistent, and companies had little visibility into timelines
• Innovation disincentive — global pharma companies sometimes deprioritised India for new drug launches, knowing the approval process was long and opaque

What Has Changed: Key Reforms

1. Approvals Now Within 150 Days

Data for the calendar year 2025 indicate that clinical trial approvals are now being processed within 120–135 days, while marketing authorizations are granted in less than 150 days. Drug Controller General of India Rajeev Singh Raghuvanshi stated that no application exceeded the 150-day mark during the year, marking a significant improvement from earlier timelines. Medical Dialogues

This is a dramatic reduction from timelines that previously stretched to 2–3 years in some cases.

2. Pre-Clinical Approval Requirement Removed

The DCGI also highlighted that the regulator has relaxed the research framework by eliminating the need for prior approval at the pre-clinical stage, thereby facilitating faster and more flexible drug development processes. 

Pre-clinical research (laboratory and animal studies conducted before human trials) no longer needs regulatory sign-off before it begins. This removes a bureaucratic hurdle that delayed even early-stage research.

3. Formal Rules for Expert Committees

India released its first official set of guidelines on how expert panels should review and approve new drugs, medical devices, and biologics. These new rules, issued by CDSCO, are designed to make the approval process quicker, more transparent, and predictable. 

The guidelines define how Subject Expert Committees (SECs) should be formed, how experts are chosen, and how they must review applications. Each SEC has eight members — one pharmacologist and seven other experts from research or medical fields. At least four members must be present to make a decision. SEC members must meet strict criteria, such as having at least 10 published research papers and a 2:1 citation ratio. They are appointed for three years and must follow rules on confidentiality, impartiality, and attendance. Business Standard

Previously, there were no formal published rules for how these committees operated — which led to variable decisions and a lack of accountability.

4. Digital Transformation: eCTD Submissions

India is transitioning to eCTD (electronic Common Technical Document) submissions, modernising dossier management. Pharmaregulatory eCTD is the global standard format used by the US FDA and EMA. Adopting it means Indian submissions are now compatible with global regulatory dossiers, reducing duplication of work for international companies and making review more efficient.

5. GMP Modernisation

CDSCO is tightening Schedule M requirements in line with WHO Good Manufacturing Practice (GMP), and pharmacovigilance reporting requirements are being enhanced through the Pharmacovigilance Programme of India (PvPI) and risk management systems. Pharmaregulatory

Better manufacturing standards mean the medicines that do reach the market are of higher and more consistent quality.

6. Fast-Track Pathways for Rare Diseases

Fast-track approvals are being introduced for rare diseases and urgent therapies InsightsIAS, mirroring similar provisions in the US (FDA Breakthrough Therapy Designation) and EU (PRIME scheme). For patients with conditions like rare cancers, lysosomal storage disorders, or other orphan diseases, this could be transformative.

To understand whether a newly approved medicine for your condition is now available in India, you can check the CDSCO approved new drugs list and then search the salt name on SearchMyMed to find available brands and formulations.

Is Faster Always Better? The Safety Balance

India is at a crossroads in its pharmaceutical regulation journey. On one hand, nimble rules can unlock innovation and global competitiveness. On the other, rushing approvals without adequate safeguards may compromise patient safety. 

The new SEC rules state that decisions like clinical trial waivers must be clearly justified, and discussions must only focus on scientific and regulatory issues — not pricing or business concerns. Business Standard This is an important safeguard against commercial pressure influencing safety decisions.

Additionally, pharmacovigilance systems are being strengthened with enhanced reporting requirements through PvPI and VigiFlow integration for reporting safety data Pharmaregulatory — meaning that even if a drug moves through approval faster, adverse events in the real world will be caught and acted upon more systematically.

What This Means for Patients and Doctors

For patients, these reforms mean:

• Newer medicines approved globally could reach India faster, within months rather than years
• Greater transparency in which drugs are under review and why decisions are made
• Better quality assurance through updated GMP standards

 

For doctors and pharmacists, it means:

• More treatment options, particularly in oncology, rare diseases, and infectious disease
• More medicines will carry eCTD-standard data packages, making prescribing information more complete and standardised

 

You can stay updated on newly approved drugs in India through the CDSCO approvals page and verify a newly approved salt's available brands by searching on SearchMyMed's salt directory.

The Road Ahead

India's pharmaceutical regulatory reform is work in progress. Challenges remain:

• Enforcement of new GMP standards across thousands of small manufacturers
• Building sufficient pharmacovigilance capacity to monitor an expanded drug portfolio
• Ensuring rural populations benefit from faster approvals, not just urban private hospitals
• Developing India's domestic rare disease drug pipeline, not just facilitating global drug entry

But the direction is clear and encouraging. A faster, more transparent, more rigorous CDSCO is good for patients, good for India's pharmaceutical industry, and good for India's ambition to be a global leader in both generic medicine supply and new drug innovation.